Mizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10

Revance Therapeutics (NASDAQ:RVNC) had its price target cut by Mizuho from $6.66 to $3.10 in a report released on Tuesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on RVNC. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Barclays reissued an “equal weight” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Revance Therapeutics in a research note on Friday, September 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Piper Sandler downgraded shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. Finally, HC Wainwright restated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $8.96.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.03 on Tuesday. The stock has a market capitalization of $317.32 million, a P/E ratio of -1.57 and a beta of 0.82. The business has a 50 day simple moving average of $4.69 and a 200 day simple moving average of $4.48. Revance Therapeutics has a one year low of $2.30 and a one year high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. Equities analysts expect that Revance Therapeutics will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Certuity LLC purchased a new stake in shares of Revance Therapeutics in the second quarter valued at about $26,000. FORA Capital LLC purchased a new stake in Revance Therapeutics in the 3rd quarter valued at about $54,000. Creative Planning bought a new position in shares of Revance Therapeutics during the 3rd quarter worth approximately $56,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Accredited Investors Inc. bought a new position in shares of Revance Therapeutics in the third quarter valued at approximately $67,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.